- Clinical-stage biopharmaceutical firm Bicara Therapeutics (BCAX) priced its preliminary public offering of 17.5M shares at $18.00 per share.
- Bicara Therapeutics’ shares are anticipated to start buying and selling on the Nasdaq Global Market on September 13, 2024 underneath the ticker image “BCAX.”
- The offering is anticipated to shut on September 16, 2024.
- Underwriters have a 30-day choice to buy as much as an extra ~2.63M shares.
- Gross proceeds are anticipated to be ~$315M.
More on Bicara Therapeutics, Inc.
Source: Seekingalpha